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Letter to the Editor 
Kaloyan Takov, Derek M Yellon, Sean M Davidson 
Luo et al. Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial 
Infarction in Mice. Circ Res. 2017; DOI 10.1161/CIRCRESAHA.116.310374. 
To the Editor: 
We were very interested by the Luo et al.1 article on the production of synthetic mesenchymal stem 
cells recently published in the Circulation Research journal. The authors manufactured microparticles 
(MPs) consisting of poly(lactic-co-glycolic acid) (PLGA)-incorporated mesenchymal stem cell (MSC)-
conditioned medium. They utilised membranes from MSCs to coat the MPs creating synthetic MSCs 
(synMSCs). Luo et al.1 showed the ability of the synMSCs for sustained release of growth factors and 
their potential for storage. Moreover, the authors demonstrated that synMSCs can increase the 
proliferative capacity and contractile function of neonatal rat cardiomyocytes in vitro, and used an in 
vivo myocardial infarction model to demonstrate the regenerative potential of the synMSCs. 
We believe this article advances the knowledge about storage and usage of MSCs and their products 
in myocardial disease. However, we would like to express some concerns and discuss a few 
important aspects of this study. 
In their in vivo mouse myocardial infarction experiments, Luo et al.1 induced a permanent left 
anterior descending (LAD) artery ligation in a mouse, followed by an intramyocardial injection of 
synMSCs or MSCs. We were somewhat concerned by the fact that, following LAD ligation, control 
group animals received no treatment while other groups received intramyocardial injections. We 
believe that the control group in such experiments must always include intramyocardial injection of 
the appropriate vehicle (PBS in this case). Previous reports have clearly shown that intramyocardial 
saline injection may induce stretch-activated myocardial protection2. Indeed, stretch-induced 
protection appears to share a common mechanism with ischemic preconditioning3. The technique of 
administration is also important, but in Luo et al.1, apart from the total volume administered (50 μl), 
details are lacking. We would be interested in knowing how many sites were injected, and with what 
volume at each site. Even the gauge of needle used is important, since too small a needle will cause 
cell shearing, while too large a needle will cause myocardial injury. 
A second point that deserves further discussion is the authors’ claim that synMSCs are superior to 
MSCs in terms of immune tolerance. Indeed, they did not observe recruitment of macrophages to 
the injection site of synMSCs, although macrophage recruitment was marked after MSCs injection. 
Firstly, since the synMSCs were coated with randomly orientated membranes from sonicated MSCs 
it is surprising that macrophages did not recognize exposed phosphatidylserine (the “eat-me” 
signal4). Secondly, MSCs are negative for MHC class II molecules5 and have low immunogenicity, with 
reports suggesting they may have anti-immunogenic and immunomodulatory functions6,7. 
Furthermore, there is evidence that macrophages that are recruited by MSCs may be beneficial in 
wound healing8, and macrophages are important players in post-myocardial infarction wound 
healing and angiogenesis9. In their experiments, Luo. et al.1 appear to have injected the MSCs 
immediately after thawing without plating and growing them in culture, since they state the 
preparation contains “dead MSC caused by harsh freezing/thawing”. Injection of dead cells seems 
highly inadvisable as such damage-associated molecular patterns (DAMPs) can activate 
inflammatory and pyroptotic death pathways in addition to efficiently recruit macrophages10. We 
are interested to know whether the authors observed similar macrophage recruitment after 
injection of MSCs prepared from growing cultures of MSCs as opposed to freshly thawed cells. 
Lastly, the authors mention exosomes and their potential for mediating some of the paracrine 
cardiovascular benefits of MSCs11, but do not present any results regarding this. We would be 
interested to know how much of the regenerative potential of the synMSCs might be due to 
exosomes contained within the conditioned medium. 
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